Home
HelpTest ID AHPM Acute Hepatitis Profile
Useful For
The differential diagnosis of recent acute viral hepatitis
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| HBAG | HBs Antigen, S | Yes | Yes |
| HBIM | HBc IgM Ab, S | Yes | Yes |
| HAVM | Hepatitis A IgM Ab, S | Yes | Yes |
| HCPCR | HCV Ab w/Reflex to HCV PCR, S | Yes | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| HCVQU | HCV RNA Detect/Quant, S | Yes | No |
| HBGNT | HBs Antigen Confirmation, S | No | No |
Testing Algorithm
If hepatitis C virus (HCV) antibody is reactive, then HCV RNA by RT-PCR will be performed at an additional charge.
If hepatitis Bs antigen is reactive, then confirmation will be performed at an additional charge.
The following algorithms are available in Special Instructions:
-HBV Infection-Diagnostic Approach and Management Algorithm
-Testing Algorithm for the Diagnosis of Hepatitis C
Special Instructions
Method Name
Chemiluminescence Immunoassay (CIA)
Reporting Name
Acute Hepatitis ProfileSpecimen Type
Serum SSTCollection Container/Tube: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 3 mL
Collection Instructions: Spin down within 6 hours of draw.
Additional Information: Date of draw is required.
Specimen Minimum Volume
2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum SST | Frozen (preferred) | 30 days |
| Refrigerated | 24 hours |
Clinical Information
Hepatitis A:
Hepatitis A virus (HAV) is an RNA virus that accounts for 20% to 25% of the viral hepatitis in United States adults. HAV infection is spread by the oral/fecal route and produces acute hepatitis which follows a benign, self-limited course. Spread of the disease is usually associated with contaminated food or water caused by poor sanitary conditions. Outbreaks frequently occur in overcrowded situations and in institutions or high density centers such as prisons and health care centers. Epidemics may occur following floods or other disaster situations. Chronic carriers of HAV have never been observed.
Hepatitis B:
Hepatitis B virus (HBV) is a DNA virus that is endemic throughout the world. The infection is spread primarily through percutaneous contact with infected blood products, eg, blood transfusion, sharing of needles by drug addicts. The virus is also found in virtually every type of human body fluid and is known to be spread through oral and genital contact. HBV can be transmitted from mother to child during delivery through contact with blood and vaginal secretions; it is not commonly transmitted transplacentally. After a course of acute illness, HBV persists in approximately 10% of patients. Some of these chronic carriers are asymptomatic, others develop chronic liver disease, including cirrhosis and hepatocellular carcinoma.
Hepatitis C:
Hepatitis C virus (HCV) is an RNA virus that is a significant cause of morbidity and mortality worldwide. HCV is transmitted through contaminated blood or blood products or through other close, personal contacts. It is recognized as the cause of most cases of posttransfusion hepatitis. HCV shows a high rate of progression (>50%) to chronic disease. In the United States, HCV infection is quite common, with an estimated 3.5 to 4 million chronic HCV carriers. Cirrhosis and hepatocellular carcinoma are sequelae of chronic HCV.
See Advances in the Laboratory Diagnosis of Hepatitis C (2002) in Publications, and HBV Infection-Diagnostic Approach and Management Algorithm and Testing Algorithm for the Diagnosis of Hepatitis C in Special Instructions.
Reference Values
HEPATITIS B SURFACE ANTIGEN
Negative
HEPATITIS B CORE ANTIBODY, IgM
Negative
HEPATITIS A IgM ANTIBODY
Negative
HEPATITIS C ANTIBODY SCREEN
Negative
Interpretation depends on clinical setting. See Viral Hepatitis Serologic Profiles in Special Instructions.
Cautions
Consider administration of immune globulin to individuals exposed to patients with hepatitis A.
Consider administration of hepatitis B immune globulin and/or hepatitis B vaccine to individuals exposed to hepatitis B patient's blood and/or body fluids.
Positive hepatitis B surface antigen and/or positive antibody to hepatitis A virus, IgM test results should be reported by the attending physician to the State Department of Health, as required by law in some states.
Performance characteristics have not been established for the following specimen characteristics:
-Grossly icteric (total bilirubin level of >15 mg/dL)
-Grossly lipemic (triolein level of >3,000 mg/dL)
-Grossly hemolyzed (hemoglobin level of >500 mg/dL)
-Containing particulate matter
-Cadaveric specimens
Day(s) Performed
Monday through Saturday; Varies
Report Available
1 dayPerforming Laboratory
Mayo Medical Laboratories in Rochester
Test Classification
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
80074-Acute hepatitis panel (includes hepatitis A IgM antibody [CPT code 86709]; hepatitis B core antibody, IgM [CPT code 86705]; hepatitis B surface antigen [CPT code 87340]; and hepatitis C antibody [CPT code 86803])
87341-HBsAG confirmation (if appropriate)
87522-Hepatitis C, quantification (if appropriate)